Skip to content
The African Exponent DATA
Resources

Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (17 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review

Africure Pharmaceuticals

No ticker printed · Stock Exchange of Mauritius · Consolidated statements

On this page
Company details
Legal name
Africure Pharmaceuticals Ltd
Listing
No ticker printed on the Stock Exchange of Mauritius, active (observed 2026-10-08)
Sector
Not classified (our classification from the stated principal activity)
Financial year ends
31 March

Overview

Year ended 31 March 2026 · annual report, final status not established · source

Read with these figures

  • Annual report not confirmed as final. The published copy is unsigned. The FY to 31 Mar 2026 figures come from it.
Full wording and sources

  • Annual report for 2026: final status not established

    The independent auditor's report (RSM (Mauritius) LLP, Ebene; Dharmanand Cushmajee, FCCA, Licensed by FRC; opinion PDF p34) is dated 07 July 2026, but both signature positions carry only a typeset 'Sd/-' above the printed firm and partner names, with no visible signature (PDF p38, page image). The statement of financial position states it was authorised for issue by the board on 06 July 2026 and likewise carries typeset 'Sd/-' marks above the names of two directors (PDF p39, page image).

    Source: Africure Pharmaceuticals Ltd & its Subsidiaries Annual Report & Financial Statements 2025-26, for the year ended 31st March 2026 (dated 2026-07-07)

  • Revenue

    USD 25.5 million

    25,494,269 USD units · p40

    Change not shown.

  • Operating profit / (loss)

    Not reported in this filing

  • Profit / (loss) for the year

    −USD 5.11 million

    (5,106,796) USD units · p41

    Change not shown.

  • Total assets

    USD 45.6 million

    45,640,057 USD units · p39

    Change not shown.

  • Total equity

    Not reported in this filing

  • Cash from operations

    USD 587,460

    587,460 USD units · p43

    Change not shown.

Large amounts are rounded for reading (USD million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.

Not shown: the two years come from different filings.

Financial statements

Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in USD units unless the row says otherwise; brackets are negative.

† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table

Column sources

  • FY to 31 Mar 2026 — annual report, final status not established; reported for the year · source
  • FY to 31 Mar 2025 — annual report, signed / final; reported for the year · source
  • FY to 31 Mar 2024 — annual report, signed / final; comparative in the FY to 31 Mar 2025 filing · source

Income statement

Income statement, USD units. Columns: FY to 31 Mar 2026 — annual report (final status not established), as reported for the year; FY to 31 Mar 2025 — annual report (signed / final), as reported for the year; FY to 31 Mar 2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY to 31 Mar 2026Annual reportreported for the yearFY to 31 Mar 2025Annual reportreported for the yearFY to 31 Mar 2024Annual reportcomparative in FY to 31 Mar 2025 filing
Revenue 25,494,269 29,766,0511 26,796,900
Other income 1,329,933 991,9052 1,472,891
Total income (unlabelled subtotal)3 26,824,202 30,757,9564 28,269,791
Cost of raw-materials and finished goods56 (14,095,009) (18,542,567)7 (15,752,734)
Employee benefit expenses8 (3,941,849) (4,089,522)9 (4,432,447)
Other expenses (4,616,714) (4,394,354)10 (3,977,884)
Total expenses (unlabelled subtotal)11 (22,653,572) (27,026,443)12 (24,163,065)
Finance costs (3,509,149) (3,116,740)13 (2,324,999)
Depreciation and amortisation14 (1,107,324) (1,512,644)15 (1,537,879)
(Loss)/Profit before income tax16 (445,843) (897,871)17 243,848
Current tax18 (2,010,334) (830,647)19 (608,067)
Deferred tax20 36,691 (26,596) (40,940)
(Loss)/Profit for the year from continued operations2122 (2,419,486) (1,755,114)23 (405,159)
Loss for the year from discontinued operations24 (2,687,310) (1,059,424)25 –26
Non-controlling interests27 (133,873) 152,339 (123,531)
(Loss)/Profit for the year28 (5,106,796) (2,814,538) (405,159)
Other comprehensive income for the year net of tax –29 –29 –29
Total comprehensive income for the year (5,106,796) (2,814,538) (405,159)
  1. Printed “-”, read as nil: subtotal_arithmetic: is.profit_for_year.
  2. Printed “-”, read as nil: subtotal_arithmetic: is.total_comprehensive_income.
Notes and alternative reported figures (27)
  1. Annual report dated 2026-07-07 prints 27,842,677 (units, p40) for this line and year.
  2. Annual report dated 2026-07-07 prints 987,141 (units, p40) for this line and year.
  3. “Total income (unlabelled subtotal)” is an issuer-specific line, not mapped to a shared definition: Unlabelled subtotal of revenue and other income (p40).
  4. Annual report dated 2026-07-07 prints 28,829,818 (units, p40) for this line and year.
  5. “Cost of raw-materials and finished goods” is an issuer-specific line, not mapped to a shared definition: Note 18: materials and finished goods consumed.
  6. Printed under different labels across filings: “Cost of raw-materials and finished goods”; “Cost of raw-materials and finished goods”.
  7. Annual report dated 2026-07-07 prints (17,386,069) (units, p40) for this line and year.
  8. Printed under different labels across filings: “Employee benefit expenses”; “Employee benefit expenses”.
  9. Annual report dated 2026-07-07 prints (3,702,937) (units, p40) for this line and year.
  10. Annual report dated 2026-07-07 prints (3,916,319) (units, p40) for this line and year.
  11. “Total expenses (unlabelled subtotal)” is an issuer-specific line, not mapped to a shared definition: Unlabelled subtotal of cost of raw-materials and finished goods, employee benefit expenses and other expenses (p40).
  12. Annual report dated 2026-07-07 prints (25,005,325) (units, p40) for this line and year.
  13. Annual report dated 2026-07-07 prints (3,024,259) (units, p40) for this line and year.
  14. “Depreciation and amortisation” is an issuer-specific line, not mapped to a shared definition: Notes 5D and 23: depreciation of property, plant and equipment and right-of-use assets with amortisation of intangibles, one line.
  15. Annual report dated 2026-07-07 prints (1,388,893) (units, p40) for this line and year.
  16. Printed under different labels across filings: “(Loss)/Profit before income tax”; “(Loss)/Profit before income tax”.
  17. Annual report dated 2026-07-07 prints (588,659) (units, p40) for this line and year.
  18. “Current tax” is an issuer-specific line, not mapped to a shared definition: Note 22: current income tax expense (no total income tax line is printed).
  19. Annual report dated 2026-07-07 prints (781,359) (units, p40) for this line and year.
  20. “Deferred tax” is an issuer-specific line, not mapped to a shared definition: Note 22A: deferred tax (no total income tax line is printed).
  21. “(Loss)/Profit for the year from continued operations” is an issuer-specific line, not mapped to a shared definition: Profit after tax from continuing operations.
  22. Printed under different labels across filings: “(Loss)/Profit for the year from continued operations”; “(Loss)/Profit for the year from continued operations”.
  23. Annual report dated 2026-07-07 prints (1,396,614) (units, p40) for this line and year.
  24. “Loss for the year from discontinued operations” is an issuer-specific line, not mapped to a shared definition: Discontinued operation.
  25. Annual report dated 2026-07-07 prints (1,417,924) (units, p40) for this line and year.
  26. “Non-controlling interests” is an issuer-specific line, not mapped to a shared definition: Profit or loss attributable to non-controlling interests.
  27. Printed under different labels across filings: “(Loss)/Profit for the year”; “(Loss)/Profit for the year”.

Balance sheet

Balance sheet, USD units. Columns: FY to 31 Mar 2026 — annual report (final status not established), as reported for the year; FY to 31 Mar 2025 — annual report (signed / final), as reported for the year; FY to 31 Mar 2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY to 31 Mar 2026Annual reportreported for the yearFY to 31 Mar 2025Annual reportreported for the yearFY to 31 Mar 2024Annual reportcomparative in FY to 31 Mar 2025 filing
Goodwill1 2,785,198 2,635,871 2,607,969
Property plant and equipment 17,879,866 15,670,285 15,744,934
Intangible assets 34,310 104,580 162,453
Right of use assets 1,728,101 2,487,717 2,624,627
Capital work in progress2 –3 7,294,453 8,034,076
Investment in subsidiaries4 –3 –3 –3
Loans and advances5 –3 –3 –3
Total non-current assets 22,427,475 28,192,906 29,360,478
Inventories 7,178,493 9,272,823 10,855,7936
Trade receivables 12,023,435 16,380,489 16,053,857
Cash and cash equivalents 1,474,285 1,325,587 1,511,754
Other assets 2,536,369 3,265,425 3,200,792
Total current assets 23,212,582 30,244,324 31,622,196
Total assets 45,640,057 58,437,230 60,982,674
Equity share capital and share premium7 10,881,853 10,881,853 10,881,853
Equity share capital pending allotment8 7,762,672 7,762,672 –9
Retained earnings (3,799,192) 1,173,731 14,208,874
Other reserves (3,792,338) (4,259,196) (4,827,146)
Capital and reserves attributable to owners of Africure Pharmaceuticals Ltd 11,052,995 15,559,060 20,263,581
Non-controlling interests (440,006) (306,133) (3,305,874)
Borrowings 16,442,808 20,435,749 16,853,087
Operating lease liabilities 3,309,550 3,904,360 3,195,689
Deferred tax liabilities 1,302,992 1,419,098 –10
Total non-current liabilities 21,055,350 25,759,207 20,048,77611
Borrowings 5,089,369 5,059,160 11,317,227
Trade and accounts payables 7,379,731 10,659,208 11,532,791
Other liabilities 1,302,574 1,123,538 782,505
Operating lease liabilities 151,534 192,358 192,358
Current tax liabilities 48,508 390,832 151,310
Total current liabilities 13,971,716 17,425,096 23,976,191
Total equity and liabilities12 45,640,057 58,437,230 60,982,674
Deferred tax asset Not reported in this filing13 –3 186,41914
  1. Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_assets.
  2. Printed “10, 855, 793”; read as 10,855,793. p26: Group 2024 printed '10, 855, 793' with stray spaces after the commas (text layer and page image p26); the text-layer reader splits it, so the cell is read on the render; the Group 2024 current assets total confirms 10,855,793.
  3. Printed “-”, read as nil: subtotal_arithmetic: bs.equity_attributable_to_owners.
  4. Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_liabilities.
  5. Printed “2,00,48,776”; read as 20,048,776. p26: Printed '2,00,48,776' in Indian digit grouping (text layer and page image p26); its three lines add to 20,048,776.
  6. Printed “1,86,419”; read as 186,419. p26: Printed '1,86,419' in Indian digit grouping (text layer and page image p26); the Group 2024 non-current assets total confirms 186,419.
Notes and alternative reported figures (8)
  1. “Goodwill” is an issuer-specific line, not mapped to a shared definition: Note 5E.
  2. “Capital work in progress” is an issuer-specific line, not mapped to a shared definition: Note 5C.
  3. “Investment in subsidiaries” is an issuer-specific line, not mapped to a shared definition: Note 6: Company-only line (Group columns print a dash).
  4. “Loans and advances” is an issuer-specific line, not mapped to a shared definition: Note 6A: non-current; Company-only line (Group columns print a dash).
  5. “Equity share capital and share premium” is an issuer-specific line, not mapped to a shared definition: Note 14: share capital and share premium in one line.
  6. “Equity share capital pending allotment” is an issuer-specific line, not mapped to a shared definition: Note 14B: funds injected for which no shares have yet been issued (p42).
  7. Printed under different labels across filings: “Total equity and liabilities”; “Total liabilities”.
  8. Not reported in this filing: Not reported in this filing: the FY2026 consolidated statement of financial position (p39) has no 'Deferred tax asset' line in either column; non-current assets are 'Goodwill', 'Property plant and equipment', 'Intangible assets', 'Right of use assets', 'Capital work in progress', 'Investment in subsidiaries' and 'Loans and advances'. The only deferred-tax line is 'Deferred tax liabilities' 1,302,992 (non-current liabilities). Checked on the page image (p39).

Cash flow

Cash flow, USD units. Columns: FY to 31 Mar 2026 — annual report (final status not established), as reported for the year; FY to 31 Mar 2025 — annual report (signed / final), as reported for the year; FY to 31 Mar 2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY to 31 Mar 2026Annual reportreported for the yearFY to 31 Mar 2025Annual reportreported for the yearFY to 31 Mar 2024Annual reportcomparative in FY to 31 Mar 2025 filing
Cash generated from operations 2,940,118 3,446,934 3,595,033
Net income tax paid (2,352,658) (591,125) (870,222)
Net cash (used in)/generated from operating activities (A)1 587,460 2,855,809 2,724,811
Capital expenditure on PPE and intangible assets incl. capital WIP23 (793,787) (503,589) (1,085,357)
Non-current loans and advances45 –6 –6 –6
Proceeds from sale of subsidiary7 8,185,042 Not reported in this filing98 Not reported in this filing9
Net cash flow (used in)/from investing activities (B)10 7,391,255 (503,589) (1,085,357)
Net cashflow from Borrowings1112 (3,962,732) 404,678 3,435,896
Repayment of operating lease liability including interest thereon13 (774,531) (315,833) (355,947)
Finance costs paid14 (3,084,738) (2,627,232) (2,162,003)
Net cash flow from/(used in) financing activities (C)15 (7,822,001) (2,538,387) (2,528,840)
Net (decrease)/increase in cash and cash equivalents (A+B+C)16 156,714 (186,167) (889,386)
Cash and cash equivalents at the beginning of the year17 1,325,587 1,511,754 2,401,141
Less: Cash and cash equivalents sold as part of sale of subsidiary18 (8,016) Not reported in this filing198 Not reported in this filing19
Cash and cash equivalents at the end of the year 1,474,285 1,325,587 1,511,755
Proceeds from Term loans2021 Not reported in this filing22 –23 (3,446,789)
  1. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
  2. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_financing.
Notes and alternative reported figures (21)
  1. Printed under different labels across filings: “Net cash (used in)/generated from operating activities (A)”; “Net cash flow from operating activities (A)”.
  2. “Capital expenditure on PPE and intangible assets incl. capital WIP”: mapping to a shared definition is uncertain. One line for property, plant and equipment, intangible assets and capital work in progress.
  3. Printed under different labels across filings: “Capital expenditure on PPE and intangible assets incl. capital WIP”; “Capital expenditure on property plant and equipment and intangible assets including Capital work in progress”.
  4. “Non-current loans and advances” is an issuer-specific line, not mapped to a shared definition: Investing activities; Company-only line (Group columns print a dash).
  5. Printed under different labels across filings: “Non current loans and advances”; “Non-current loans and advances”.
  6. “Proceeds from sale of subsidiary” is an issuer-specific line, not mapped to a shared definition: Investing activities.
  7. Annual report dated 2026-07-07 presents this line for this year: - (p43). Not shown in this column, which follows one filing's presentation.
  8. Not reported in this filing: Not reported in this filing: no 'Proceeds from sale of subsidiary' line; the FY2025 consolidated statement of cashflows (p30) has no such line in any column; its investing lines are 'Capital expenditure on property plant and equipment and intangible assets including Capital work in progress' and 'Non current loans and advances', and the closing cash is reached without a deduction for cash sold. (The line first appears in the FY2026 report for 2026.) Checked on the page image (p30).
  9. Printed under different labels across filings: “Net cash flow used in investing activities (B)”; “Net cash flow (used in)/from investing activities (B)”.
  10. “Net cashflow from Borrowings” is an issuer-specific line, not mapped to a shared definition: Financing activities: borrowings drawn net of repayments, one line.
  11. Printed under different labels across filings: “Net cashflow from Borrowings*”; “Net cashflow from Borrowings”.
  12. “Repayment of operating lease liability including interest thereon” is an issuer-specific line, not mapped to a shared definition: Financing activities: lease principal and interest, one line.
  13. “Finance costs paid” is an issuer-specific line, not mapped to a shared definition: Financing activities: interest paid.
  14. Printed under different labels across filings: “Net cash flow from financing activities (C)”; “Net cash flow from/(used in) financing activities (C)”.
  15. Printed under different labels across filings: “Net (decrease)/ increase in cash and cash equivalents (A+B+C)”; “Net (decrease)/increase in cash and cash equivalents (A+B+C)”.
  16. Printed under different labels across filings: “Add: Cash and cash equivalents at the beginning of the year”; “Cash and cash equivalents at the beginning of the year”.
  17. “Less: Cash and cash equivalents sold as part of sale of subsidiary” is an issuer-specific line, not mapped to a shared definition: Reconciling line between opening and closing cash: cash of the subsidiary sold.
  18. Not reported in this filing: Not reported in this filing: no 'Less: Cash and cash equivalents sold as part of sale of subsidiary' line; the FY2025 consolidated statement of cashflows (p30) has no such line in any column; its investing lines are 'Capital expenditure on property plant and equipment and intangible assets including Capital work in progress' and 'Non current loans and advances', and the closing cash is reached without a deduction for cash sold. (The line first appears in the FY2026 report for 2026.) Checked on the page image (p30).
  19. “Proceeds from Term loans” is an issuer-specific line, not mapped to a shared definition: Financing activities: printed 'Proceeds from Term loans' (an outflow in 2024).
  20. “Proceeds from Term loans”: mapping to a shared definition is uncertain. Printed 'Proceeds from Term loans' but the 2024 amount is an outflow in brackets.
  21. Not reported in this filing: Not reported in this filing: the FY2026 consolidated statement of cashflow (p43) has no 'Proceeds from Term loans' line in either column; its financing lines are 'Net cashflow from Borrowings', 'Repayment of operating lease liability including interest thereon' and 'Finance costs paid'. Checked on the page image (p43).

Per share and shares

Per share and shares. Columns: FY to 31 Mar 2026 — annual report (final status not established), as reported for the year; FY to 31 Mar 2025 — annual report (signed / final), as reported for the year; FY to 31 Mar 2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY to 31 Mar 2026Annual reportreported for the yearFY to 31 Mar 2025Annual reportreported for the yearFY to 31 Mar 2024Annual reportcomparative in FY to 31 Mar 2025 filing
Earnings / (loss) per share (per share)2 Not yet collected from the source1 (0.3) (0.04)
Profit / (loss) attributable to shareholders (USD units)3 (4,972,923) (2,966,877) (281,628)
Weighted average shares (shares)4 9,417,500 9,417,500 9,417,500
Notes and alternative reported figures (4)
  1. Not yet collected from the source: Printed in whole dollars ((1) Group 2026; dash 2025; diluted dash against basic (1)) and inconsistent with the printed loss and weighted shares at that rounding (p40); left for a person to judge.
  2. Earnings / (loss) per share: printed as “Basic earnings per share”.
  3. Profit / (loss) attributable to shareholders: printed as “Owners of the Company”.
  4. Weighted average shares: printed as “Weighted average number of shares”.

Reported measures outside the statements

Issuer-reported EBITDA, as printed outside the primary statements; definition and scope are the issuer's. Printed 'Profit before finance cost, depreciation and tax': earnings before finance costs, depreciation, amortisation and tax, as presented by the issuer.
Measure (as printed)FY to 31 Mar 2026FY to 31 Mar 2025FY to 31 Mar 2024
Profit before finance cost, depreciation and tax4,170,630 p403,731,513 p284,106,726 p28

Segments

Segment data not yet collected for this company in the pilot.

Dividends

Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.

No dividend statement or amount collected.

Sources

Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.

  • Africure Pharmaceuticals Ltd & its Subsidiaries Annual Report & Financial Statements 2025-26, for the year ended 31st March 2026

    Year ended 31 March 2026 · Annual report · final status not established

    Audit: RSM (Mauritius) LLP, Ebene, unmodified opinion

    Auditor's sign-off: RSM (Mauritius) LLP; Dharmanand Cushmajee, FCCA (names printed under typeset 'Sd/-')

    Final status: The independent auditor's report (RSM (Mauritius) LLP, Ebene; Dharmanand Cushmajee, FCCA, Licensed by FRC; opinion PDF p34) is dated 07 July 2026, but both signature positions carry only a typeset 'Sd/-' above the printed firm and partner names, with no visible signature (PDF p38, page image). The statement of financial position states it was authorised for issue by the board on 06 July 2026 and likewise carries typeset 'Sd/-' marks above the names of two directors (PDF p39, page image).

    Document date
    7 Jul 2026
    Auditor's report
    7 Jul 2026
    Board approval
    6 Jul 2026
    Retrieved by us
    8 Oct 2026 (not a publication date)
    Used for
    statement columns FY to 31 Mar 2026
    Basis
    consolidated statements · USD units (printed “all amounts in USD unless otherwise stated”)
    • Earnings per share is printed in whole dollars: basic (1) for the Group in 2026 and a dash for 2025, diluted a dash for the Group in 2026 against basic (1) (p40); loss attributable to owners over the weighted average shares printed is about (0.53) and (0.32). Not transcribed (gap).
    • Equity attributable to owners, non-controlling interests, total non-current and total current liabilities add to 45,640,055 against the printed total equity and liabilities of 45,640,057 in 2026 (2025 adds exactly to 58,437,230) (p39, checked on the page image); kept as printed.
    • Cash at the end of the year is reached after a separate line for cash sold with a subsidiary ((8,016); 2025: dash) (p43) (presented within the bridge to closing cash). The 2025 Group depreciation add-back in the cash flow statement (1,512,644) differs from the 2025 statement of profit or loss (1,388,893); the reconciliation lines are not transcribed.
    • No total equity, total liabilities, total income tax, operating profit or other comprehensive income detail is printed: equity attributable to owners (11,052,995; 2025: 15,559,060) and non-controlling interests ((440,006); 2025: (306,133)) are printed without a total (p39); current tax and deferred tax are printed without a total (p40).
    • Profit before income tax (p40) covers continuing operations only; the discontinued operation is presented after tax. The profit for the year on p40 is an unlabelled line ((5,106,796); 2025: (2,814,538)); the same figures are printed with the label '(Loss)/Profit for the year' on p41 and are read there.
    • Statements are presented in US dollars; the shares are quoted on the SEM as 'AFRICURE (USD)'.
    Technical details
    File
    74 pages, with a text layer
    SHA-256
    b427c04e702b1ab7a65a6260cab8f9d0ff593e409b9aa2b6e749823df90c3fd5
    Entity as printed
    Africure Pharmaceuticals Ltd (the Company) and its subsidiaries (the Group)
    Issuer copy
    retrieved 2026-10-08T19:13:02Z

  • Africure Pharmaceuticals Ltd Annual Report 2024-25

    Year ended 31 March 2025 · Annual report · signed / final

    Audit: RSM (Mauritius) LLP, Ebene, unmodified opinion · signed

    Auditor's sign-off: RSM (Mauritius) LLP; Dharmanand Cushmajee, FCCA, Licensed by FRC

    Final status: Independent auditor's report (opinion PDF p21) with a handwritten 'RSM' signature above 'RSM (Mauritius) LLP, Ebene, Mauritius' and a handwritten signature above 'Dharmanand Cushmajee, FCCA, Licensed by FRC', 'Date: 30 July 2025' (PDF p25, page image). The statement of financial position was authorised for issue by the board on 30 July 2025 and carries two DocuSign signatures (Mr. Sultunti Asnath, Mr. Vashish Bisnathsing, directors) (PDF p27, page image).

    Document date
    30 Jul 2025
    Auditor's report
    30 Jul 2025
    Board approval
    30 Jul 2025
    Retrieved by us
    8 Oct 2026 (not a publication date)
    Used for
    statement columns FY to 31 Mar 2025, FY to 31 Mar 2024
    Basis
    consolidated statements · USD units (printed “All the amounts are in USD unless otherwise stated”)
    • Cash flow statement (p30): the indirect-method reconciliation does not reconcile as printed (e.g. 'Operating profit before working capital changes' 25,93,231 against adjustments totalling 4,550,526; finance costs added back 2,792,959 against 3,116,740 in profit or loss; a working-capital amount printed '(3.200.799)'); the cash-flow loss before tax (1,957,295) includes the discontinued operation. Closing cash 2024 is printed 1,511,755 in the cash flow statement and 1,511,754 in the statement of financial position and as 2025 opening cash. Only the lines from 'Cash generated from operations' are transcribed.
    • Group 2024 basic and diluted EPS are printed (0.04) (p28), but the loss attributable to owners (281,628) over the weighted average shares printed (9,417,500) gives (0.03); kept as printed (EPS check fails for 2024). Group 2024 net cash from financing is printed (2,528,840) against (2,528,843) from its printed lines (issuer rounding, p30).
    • EPS is printed to one or two decimals in USD (Group (0.3); 2024: (0.04)); basic and diluted equal. The 2024 comparatives here differ from the 2025 comparatives in the FY2026 report (e.g. Group other income 991,905 here against 1,226,720 there): the FY2026 report re-presents 2025.
    • Indian digit grouping and stray spaces are printed in some cells (text layer and page image): Group 2024 deferred tax asset '1,86,419' and total non-current liabilities '2,00,48,776' (read as printed; the subtotals confirm 186,419 and 20,048,776); Group 2024 inventories '10, 855, 793' (read on the render as 10,855,793, interpreted; current assets confirm it).
    • No total equity, total income tax or operating-profit line is printed; the line printed 'Total liabilities' (p27) is the total of equity and liabilities (58,437,230 = total assets). The expense lines and their unlabelled subtotal (p28) are printed without brackets and deducted from total income; stored negative.
    Technical details
    File
    72 pages, with a text layer
    SHA-256
    8fe205258b0758300771f02bfbb874cb9fff8831645c137e73fef335b7c50265
    Entity as printed
    Africure Pharmaceuticals Ltd (the Company) and its subsidiaries (the Group)
    Issuer copy
    retrieved 2026-10-08T19:13:12Z

Data notes

  • Deferred tax asset — Printed '1,86,419'; read as '186,419'. Printed '1,86,419' in Indian digit grouping (text layer and page image p26); the Group 2024 non-current assets total confirms 186,419. (Africure Pharmaceuticals Ltd Annual Report 2024-25, p26)
  • Inventories — Printed '10, 855, 793'; read as '10,855,793'. Group 2024 printed '10, 855, 793' with stray spaces after the commas (text layer and page image p26); the text-layer reader splits it, so the cell is read on the render; the Group 2024 current assets total confirms 10,855,793. (Africure Pharmaceuticals Ltd Annual Report 2024-25, p26)
  • Total non-current liabilities — Printed '2,00,48,776'; read as '20,048,776'. Printed '2,00,48,776' in Indian digit grouping (text layer and page image p26); its three lines add to 20,048,776. (Africure Pharmaceuticals Ltd Annual Report 2024-25, p26)

Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (17 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.

Download

Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.

· Company methodology and coverage